Manufacturing roundup: Novartis licenses Alteogen's Hybrozyme tech; Cellares cuts 68 more NJ jobs; Novonesis, Aspen, Fortrea and Northway expand.
Plus, news about Novonesis, Aspen, Fortrea and Northway.
Alteogen and Novartis make a deal: The Swiss pharma is licensing Alteogen’s hyaluronidase …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth…
Two Big Pharmas are shrinking their U.S. | AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California,…
Novo Nordisk invests ~$380M in Czech manufacturing and $29.4M in China; Cellares grows Series D to $327M; Eisai gets support;…
Genentech builds $750M OR facility; Bavarian Nordic delays Lyme vaccine to 2028; Xspray gets 2nd CRL for Dasynoc over NerPharMa…
Novartis plans to cut up to 130 Basel jobs as biologics work shifts to other sites and its campus.
A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a standoff.…
